Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study.
O’Kelly B 1,2, Vidal L 2, McHugh T 2, et. al. Brain, Behavior, & Immunity – Health, 03 Jul 2022, 24:100485, https://doi.org/10.1016/j.bbih.2022.100485 PMID: 35814187 PMCID: PMC9250701 Abstract Background Up to 37.7% of patients experience symptoms beyond 12 weeks after infection with SARS-CoV-2. To date care for people with long covid has centred around multidisciplinary rehabilitation, self care and self pacing. No pharmacotherapy has been […]